Explain this page
Arphra AIPlain-English read on Pfizer Inc.’s valuation06-08today
- Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?14h
- PFE Stock Slides Following CFO Exit, 2026 Guidance Reaffirmed1d
- Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook2d
- Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors2d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$77.72
+208.16% vs spot
Recommendation
Strong Buy
18 of 19 methods
Method spread
14bull3bear
±5% threshold
Analyst PT consensus: $26.75 (+6.07%)
Candlestick · 1Y
Open in chart workstation →PFE
25.21+4.91%H 28.75L 23.11MA50 26.25MA200 25.88Avg vol 48.5M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.70% | -3.92% | -2.81% | -6.49% | +0.12% | +1.29% | +4.95% | -35.17% | -36.02% | -23.44% | +5771.53% |
Insider · 30d
History →Bought
$527.31K
2 txns
Sold
$116.23K
2 txns
Net flow
+$411.09K
Aftermarket
LiveLast trade
$25.25
Bid
$25.24
13,800 sh
Ask
$25.28
15,700 sh
Spread
$0.040
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $17.56B | -$1.65B | $-0.29 |
| Q3 Sep 2025 | $16.65B | $3.54B | $0.62 |
| Q2 Jun 2025 | $14.65B | $2.91B | $0.51 |
| Q1 Mar 2025 | $13.72B | $2.97B | $0.52 |
| Q4 Dec 2024 | $17.76B | $403M | $0.07 |
| Q3 Sep 2024 | $17.7B | $4.47B | $0.78 |
Analyst view
DB · price_targets + analyst_gradesConsensus target
$26.75
+6.07% upside
Low
$25.00
Median
$27.00
High
$30.00
Recent actions
0 ↑0 ↓8 hold
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
- Dec 01, 2025
News
DB · news_items- Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?fool.com·Jun 20, 2026
- PFE Stock Slides Following CFO Exit, 2026 Guidance Reaffirmedzacks.com·Jun 19, 2026
- Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlookfool.com·Jun 18, 2026
- Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investorszacks.com·Jun 18, 2026
- Pfizer Stock Drops Today As CFO Steps Down In Augustbenzinga.com·Jun 18, 2026
- Can Pfizer Take Share From Lilly & Novo Nordisk in the Obesity Space?zacks.com·Jun 18, 2026
- Pfizer CFO Dave Denton to step down, leave company in Augustreuters.com·Jun 18, 2026
- Pfizer Announces Chief Financial Officer Transitionbusinesswire.com·Jun 18, 2026
Recent analyst activity
DB- Jun 09, 2026GradeUnderperform → Sector PerformPfizer upgraded to Sector Perform from Underperform at RBC CapitalRBC Capital
- Jun 01, 2026GradeNeutral → NeutralPfizer (PFE) Reiterates at Neutral by Cantor FitzgeraldCantor Fitzgerald
Financial scores
DBJun 19, 2026Altman Z
2.05
Grey
≥ 3.0 safe · 1.81–3.0 grey · < 1.81 distress
Piotroski F
5/9
Average
≥ 7 strong · 4–6 average · < 4 weak
Peers
Total assets
$208.16B
Total debt
$67.42B
Cash & equiv
$1.14B
Operating CF
$11.71B
Free cash flow
$9.08B
Buybacks
$0
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
DAMICO JENNIFER B. officer: SVP & Controller | Sell | 2,000 | $51.4K | Jun 09, 2026 |
DAMICO JENNIFER B. officer: SVP & Controller | Sell | 2,500 | $64.83K | Mar 04, 2025 |
BLAYLOCK RONALD E director | Buy | 19,457 | $499.07K | Feb 13, 2025 |
Gottlieb Scott director | Buy | 1,000 | $28.24K | Oct 30, 2024 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $62.58B | $15.44B | $7.77B | $1.36 | +12.42% |
| FY 2024 | $63.63B | $16.48B | $8.02B | $1.41 | +12.60% |
| FY 2023 | $59.55B | $5.29B | $2.13B | $0.37 | +3.58% |
| FY 2022 | $100.33B | $37.55B | $31.37B | $5.47 | +31.26% |
| FY 2021 | $81.29B | $20.79B | $22.15B | $3.88 | +27.25% |